Category: Pα+ - Psychedelic Alpha

Part 2 of our Year in Review video series is out now.

Read more about the article Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus

Post published:January 8, 2026
Post category:Psychedelic Bulletin Pα+

Read more about the article 2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: Future(s) & Open Questions (Video)

Post published:January 6, 2026
Post category:2025 Year in Review Analysis News Pα+

Read more about the article 2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Post published:December 30, 2025
Post category:2025 Year in Review Analysis News Pα+

Read more about the article 2025 Year in Review: Psychedelics in 2025 (Video)

2025 Year in Review: Psychedelics in 2025 (Video)

Post published:December 23, 2025
Post category:2025 Year in Review Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin Accelerates Brain Tumour Growth in Mice; Texas’ $50M Ibogaine Study Consortium

Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin Accelerates Brain Tumour Growth in Mice; Texas’ $50M Ibogaine Study Consortium

Post published:December 17, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

Post published:December 10, 2025
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout Plans

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout Plans

Post published:December 5, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

Post published:December 3, 2025
Post category:Analysis News Pα+

Read more about the article Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Post published:November 26, 2025
Post category:Interviews Pα+

Read more about the article ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics

Post published:November 22, 2025
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.